Company: REVB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0000950170-25-066897
Chunk: 3

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 3
---
 for personnel involved in executive, finance and other administrative functions. We expect our general and administrative expenses to increase for the foreseeable future as we increase the size of our administrative function to support the growth of our business and support our continued research and development activities. We also anticipate increased expenses as we continue to operate as a public company, including increased expenses related to financial advisory services, audit, legal, regulatory, investor relations costs, director and officer insurance premiums associated with maintaining compliance with exchange listing and SEC requirements.

Other (Expense) Income, Net

Other (expense) income, net primarily consists of the change in fair value of warrant liability, clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses, interest expense and interest income from our cash balances in savings accounts.

Results of Operations

The following table summarizes our results of operations for the periods presented:

                                         Three Months Ended                                                                      
                                         March 31,                                                                               
                                         2025                                    2024                      Change                
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Operating expenses:                                                                                                            
  Research and development               $                          858,830      $            717,582      $            141,248  
  General and administrative                                      1,236,157                 1,184,556                    51,601  
  Total operating expenses                                        2,094,987                 1,902,138                   192,849  
  Loss from operations                                           (2,094,987                (1,902,138                  (192,849  
  Total other income (expense), net                                  43,902                  (779,295                   823,197  
  Net loss                               $                       (2,051,085      $         (2,681,433      $            630,348  

Research and Development Expenses

The following table summarizes our research and development expenses for the periods presented:

                                                               Three Months Ended                                                               
                                                               March 31,                                                                        
                                                               2025                                 2024                   Change               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses         $                       470,578      $         333,225      $           137,353  
  Other expenses                                                                        23,613                 89,015                  (65,402  
  Personnel expenses (including stock-based compensation